Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsWPS Health Insurance Prior Auth Drug List | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentWPS Health InsurancePolicy 32009-100-2608

    Why do some drugs require prior authorization

    Customize your policy alerts

    Sign up for WPS Health Insurance Policy 32009-100-2608 alerts

    Get alerted when Policy 32009-100-2608 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Describes why certain drugs require prior authorization, who performs reviews, where to get criteria, and provides a list of drugs requiring PA for WPS Health Insurance members and delegated vendors.

    Policy Summary
    PayerWPS Health Insurance
    PolicyWhy do some drugs require prior authorization
    Policy CodePolicy 32009-100-2608
    Change TypeAdministrative update
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit the request to the designated reviewer (ESI, CCUM, eviCore, or WPS) with the drug identifier, benefit type, and HCPCS/J-code as applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All listed drugsrequire prior authorization
    8/1/2026effective date
    44document pages
    ESI/CCUM/eviCorereviewers listed
    1-800-475-1954contact

    Coverage Criteria

    General coverage stance

    Covered when medical necessity is met and prior authorization is approved

    General coverage stance: Coverage is provided when the requested drug meets the plan's medical necessity requirements and a prior authorization (PA) has been obtained and approved.

    Services deemed experimental, investigational, or unproven per clinical guidelines are not covered. If delegated reviewers (ESI, CCUM, eviCore) cannot complete the review, submit to WPS; if the group uses a different PBM, submit to that PBM.

    Initial coverage requirement

    Covered only with prior authorization when submitted to designated reviewer

    Initial coverage requirement: All listed drugs require prior authorization and the PA request must be submitted to the reviewer specified for the drug (ESI, CCUM, eviCore, or WPS).

    Per‑drug entries include benefit type, HCPCS/J‑codes, and the designated reviewer; no clinical entry‑level criteria are provided in these chunks.

    Policy Summary
    PayerWPS Health Insurance
    PolicyWhy do some drugs require prior authorization
    Policy CodePolicy 32009-100-2608
    Change TypeAdministrative update
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit the request to the designated reviewer (ESI, CCUM, eviCore, or WPS) with the drug identifier, benefit type, and HCPCS/J-code as applicable.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing CodesProvider Actions and Submission RequirementsDefinitions and Field MappingInitial Prior Authorization MetadataStep Therapy and Vendor CriteriaSite of Care and Benefit Type ImplicationsBiosimilars ListedBackground

    General PA requirement

    Covered only with prior authorization

    General PA requirement: A prior authorization must be obtained for any drug appearing on the PA list prior to coverage or claim payment.

    Reviewer routing (ESI, CCUM, eviCore) or submission to WPS is specified per drug entry; if delegated reviewers cannot complete the review, submit to WPS.

    Prior Authorization Requirement

    Covered when PA obtained

    Prior Authorization Requirement: All drugs on this list require prior authorization before coverage or reimbursement.

    If the delegated reviewer (ESI, CCUM, or eviCore) cannot complete the review, submit to WPS; if using a PBM other than ESI through WPS, submit to that PBM.

    General PA coverage condition

    Covered when prior authorization is obtained and the request is reviewed by the designated reviewer

    PA requirement: Prior authorization must be submitted for any drug on the list and directed to the reviewer specified for that drug (ESI, CCUM, eviCore, or WPS).

    Reviewer mapping and HCPCS codes are provided per drug entry; if the PBM/reviewer cannot complete review submit to WPS for evaluation.

    General PA coverage criteria (administrative — per-drug)

    Covered when PA is approved by the designated reviewer

    PA submission requirements: Provider must submit a prior authorization request for the specific drug, include the applicable HCPCS/J‑code and benefit type, and indicate the clinical indication as needed; route the request to the reviewer listed for that drug (ESI, CCUM, eviCore, or WPS).

    Document shows per‑drug reviewer assignments and comments (e.g., Oncology, MH/SUD) which should be included with the submission.

    General PA requirement and reviewer routing

    Covered only with prior authorization when routed appropriately

    PA and routing: All drugs listed require prior authorization; route the PA to ESI, CCUM, or eviCore as indicated by the drug entry. If those reviewers cannot complete the review, submit to WPS. If using a PBM other than ESI through WPS, submit to that PBM.

    Applies across the list; each drug line item lists the designated reviewer inline.

    Services determined to be experimental, investigational, or unproven under the clinical guidelines are excluded from coverage and will not be covered.

    The provided document excerpts do not list any specific drug-level exclusions beyond the general noncoverage of services deemed experimental, investigational, or unproven; this portion functions as a roster of drugs requiring prior authorization rather than an exclusions list.

    All drugs on the list require prior authorization and must be submitted to the designated reviewer (ESI, CCUM, or eviCore). If the delegated reviewer cannot complete the review, providers should submit the PA request to WPS for evaluation; no state-specific exclusions are specified in the cited excerpts.

    These chunks do not contain drug-specific clinical coverage criteria or decision logic. They serve as an index mapping each listed drug to its benefit type, HCPCS/J-code (where provided), and assigned reviewer; clinical determination and coverage decisions are performed via the prior authorization process by the designated reviewer.

    No explicit clinical exclusions are provided in these excerpts. Some entries include a benefit-type flag (P = Pharmacy, M = Medical) and a reviewer assignment (ESI, CCUM, eviCore, or WPS), but the document portion does not enumerate indication-specific exclusions.

    The excerpts show that every drug on the roster requires prior authorization; no clinical exclusions are listed in this window. Reviewer routing (ESI for non‑oncology, eviCore for oncology, CCUM as indicated) and the policy effective date are provided, but not indication-level exclusion rules.

    In the material shown, the file indicates that all drugs listed require prior authorization; it does not provide explicit clinical exclusion criteria within these chunks.

    These excerpts reiterate that listed drugs require prior authorization and include reviewer routing and benefit-type flags, but they do not specify clinical exclusion conditions or coverage exceptions.

    No explicit clinical coverage exclusions are stated in these chunks; the content focuses on per‑drug PA requirements, billing codes, and assigned reviewers rather than on conditions that would exclude coverage.

    Within this excerpt there are no clinical exclusions listed for the drugs. The document consistently requires prior authorization and specifies reviewer routing, but does not list indication-specific exclusions here.

    These chunks again show the PA requirement for all listed drugs and include HCPCS/J-codes and reviewer assignments; they do not state explicit coverage exclusions or clinical criteria that would deny coverage beyond the general noncoverage of investigational services.

    No indication-specific exclusion conditions are provided in the cited excerpts. The document portion functions as a PA-required drug list with routing information rather than an exclusions table.

    The provided material focuses on listing drugs that require prior authorization and indicating reviewer routing; it does not include explicit clinical exclusions in these excerpts.

    Coding and Billing Codes

    Listed HCPCS/CPT codes in drug listHCPCS
    J3490Listed as HCPCS for multiple topical and pharmacy drugs (e.g., 5-fluorouracil - topical, adapalene/benzoyl peroxide)
    J91905-fluorouracil - injection
    J0129Abatacept
    J8999Multiple oral oncology agents (e.g., abemaciclib, afatinib)
    J9354ado-trastuzumab emtansine
    J0172aducanumab-avwa
    J7352afamelanotide acetate
    Q2057afamitresgene autoleucel
    J0177aflibercept (HD)
    J0178aflibercept (HD)
    1–10 of 26
    1/3
    Listed HCPCS/J/Q/C codes in this chunk rangeHCPCS
    Q2057afamitresgene autoleucel HCPCS Code (as listed)
    J0177aflibercept (HD) HCPCS Code
    J0178aflibercept (HD) HCPCS Code
    C9161aflibercept-abzv HCPCS Code
    Q5149aflibercept-abzv / various biosimilars HCPCS Code
    Q5147aflibercept-ayyh HCPCS Code
    Q5170aflibercept-boav HCPCS Code
    Q5155aflibercept-jbvf HCPCS Code
    Q5150aflibercept-mrbb HCPCS Code
    Q5153aflibercept-yszy HCPCS Code
    1–10 of 40
    1/4
    Listed HCPCS/J/Q codesmixed
    J3590listed for apremilast (example)
    C9145listed for aprepitant - IV
    J8502listed for aprepitant - IV
    J8501listed for aprepitant - oral
    J8499multiple oral/injectable drugs (general HCPCS mapping)
    J9017arsenic trioxide
    J9022atezolizumab
    J9024atezolizumab and hyaluronidase-tqjs
    J2782avacincaptad pegol
    C9162avacincaptad pegol
    1–10 of 21
    1/3
    Sample HCPCS/HCPCS-like codes shownHCPCS
    J8499listed as HCPCS/charge code for multiple drugs (example: budesonide)
    J0584burosumab-twza (CRYSVITA) HCPCS indicated
    J0598CINRYZE HCPCS
    J0597BERINERT HCPCS
    J0599HAEGARDA HCPCS
    Oncology HCPCS entriesHCPCS
    J9043cabazitaxel HCPCS
    J9064alternate cabazitaxel HCPCS
    J9118calaspargase pegol-mknl HCPCS
    J8999miscellaneous antineoplastic drugs HCPCS (used for oral cabozantinib entry)
    CAR-T and other specialty therapy codesmixed
    C9098ciltacabtagene autoleucel HCPCS/C-code
    Q2056ciltacabtagene autoleucel alternate code
    J1203cipaglucosidase alfa-atga HCPCS
    J9060cisplatin HCPCS
    Listed HCPCS/J-codes and other codesmixed
    J9075cyclophosphamide - inj
    J9071cyclophosphamide - inj (auromedic)
    J9076cyclophosphamide - inj (baxter)
    J9072cyclophosphamide - inj (dr reddy's)
    J9073cyclophosphamide - inj (ingenus)
    J9074cyclophosphamide - inj (sandoz)
    J8499cysteamine bitartrate / many other pharmacy agents
    J9100cytarabine
    J0850cytomegalovirus immune globulin (CYTOGAM)
    J8999dabrafenib - oral and other oral oncologic agents
    1–10 of 36
    1/4
    Listed HCPCS/J and other billing codes in this sectionHCPCS
    J1301HCPCS code listed for edaravone
    J9334HCPCS code listed for efgartigimod alfa and hyaluronidase-
    J9332HCPCS code listed for efgartigimod alfa-fcab
    J1449HCPCS code appearing with eflapegrastim-xnst and related agents
    J3490Miscellaneous HCPCS code appearing with gene therapies and other
    J3590Miscellaneous HCPCS code appearing with gene therapies and other
    C9399Not otherwise classified drug code shown for several products
    J1322HCPCS code listed for elosulfase alfa
    J9176HCPCS code listed for elotuzumab
    J7170HCPCS code listed for emicizumab-kxwh
    1–10 of 32
    1/4
    Examples of HCPCS codes in listHCPCS
    J7178fibrinogen concentrate (human) - HCPCS listed
    J7177fibrinogen concentrate (human) - HCPCS listed
    Additional HCPCS examplesHCPCS
    J1442filgrastim - HCPCS listed
    J8499multiple products listed with J8499
    J9200floxuridine - HCPCS listed
    More HCPCS codesHCPCS
    J1610glucagon - HCPCS listed
    J1595glatiramer acetate - HCPCS listed
    Gene/CAR-T and specialty therapy codesHCPCS|CPT|NDC|mixed
    J1744icatibant acetate - HCPCS listed
    J9211idarubicin hcl - HCPCS listed
    C9081idecabtagene vicleucel - HCPCS/C-code listed
    Q2055idecabtagene vicleucel - Q-code listed
    Covered HCPCS/J codes in this chunkHCPCSCovered
    J1744icatibant acetate
    J9211idarubicin hcl - inj
    C9081idecabtagene vicleucel
    Q2055idecabtagene vicleucel
    J8999idelalisib - oral (listed under J8999)
    J1743idursulfase
    J9208ifosfamide
    J1575igg/hyaluronidase, recombinant (HYQVIA)
    Additional HCPCS/J/C/C9399/J8499 codes in later chunksHCPCSCovered
    J1786imiglucerase
    J3490imiquimod (listed under J3490)
    J1572imm glob g (igg)/sorb/iga 0-50 (FLEBOGAMMA)
    J1562imm glob sc/scig/igsc (VIVAGLOBIN)
    J1557immun glob g(igg)/gly/iga 0-50 (GAMMAPLEX)
    J1555immun glob g(igg)/gly/iga ov50 (CUVITRU)
    J1556immun glob g(igg)/gly/iga ov50 (BIVIGAM)
    J1569GAMMAGARD LIQUID
    J1459immun glob g(igg)/pro/iga 0-50 (PRIVIGEN)
    J1559HIZENTRA
    1–10 of 37
    1/4
    Sample HCPCS/J Codes from list (partial)HCPCS
    J8999listed as HCPCS/J-code for multiple oral oncology pharmacy items (example: ivosidenib, ixazomib)
    J9207ixabepilone
    J3590ixekizumab
    J3490ketorolac ophthalmic and others
    C9399ketorolac tromethamine
    Additional HCPCS/J Codes (partial)HCPCS
    J8499multiple drug entries (e.g., ledipasvir/sofosbuvir, lemborexant)
    J0738lenacapavir (injectable)
    J9359loncastuximab tesirine-lpyl
    J1930lanreotide
    Sample HCPCS codes from list (partial)HCPCS
    J8499listed as HCPCS code for multiple pharmacy drugs
    J9250methotrexate-related HCPCS mapping referenced
    J9260alternative methotrexate-related HCPCS mapping
    J0887methoxy peg-epoetin beta HCPCS
    Oncology and specialty HCPCS (partial)HCPCS
    J8999placeholder/other HCPCS for many oral oncology agents
    J2326nusinersen HCPCS
    J2350ocrelizumab HCPCS
    Sample HCPCS/J-codes from entriesHCPCS
    J0585listed with abeparvovec-brve/onabotulinumtoxin a (from line text)
    J3405intrathecal entry
    C9309intrathecal entry
    Additional HCPCS/J-codesHCPCS
    J8499multiple oral and pharmacy-designated drugs
    J9263oxaliplatin
    90378palivizumab
    Further HCPCS/J-codesHCPCS
    J2507pegloticase (KRYSTEXXA)
    J2502pasireotide
    J9271pembrolizumab
    HCPCS/J Codes (sample from excerpt)HCPCS
    J8999listed next to certain drugs (see document)
    S0182listed next to J8999 in this excerpt
    HCPCS/J/Q Codes (examples)HCPCS
    A9606radium-223 dichloride HCPCS
    J9308ramucirumab HCPCS
    J2778ranibizumab HCPCS
    Oncology-related J-codes (examples)HCPCS
    J9310rituximab HCPCS
    J9317sacituzumab govitecan-hziy HCPCS
    J2783rasburicase HCPCS
    Sample HCPCS codes (per-drug entries)HCPCS
    J2860siltuximab (example from list)
    HCPCS/CPT-like codes referenced across entriesHCPCS
    J8499Multiple oral/IV drugs listed with J8499 as billing code placeholder
    J3490Multiple entries use J3490
    J9249Example — various J-codes shown across list (specific codes per drug vary)
    J3241Example code present for teprotumumab-trbw
    J9274Example code present for teclistamab-cqyv
    Q2042CAR-T therapy code (tisagenlecleucel)
    J3055Code listed for talquetamab-tgvs
    J1302Code listed for sutimlimab - jome
    J9331Code listed for sirolimus protein-bound particles (FYARRO)
    J3240Code listed for thyrotropin alfa (THYROGEN)
    Sample HCPCS/CPT/ Misc codes from listmixed
    J3240thyrotropin alfa
    J3245tildrakizumab
    J3490timolol ophthalmic / tirbanibulin / tirzepatide (listed as J3490 in some entries)
    J8499timothy grass pollen allergen / tiopronin / many pharmacy-designated items
    Additional HCPCS/CPT codesmixed
    J3262tocilizumab
    Q2042tisagenlecleucel
    J9351topotecan - inj
    J8999various oral oncology agents
    J9352trabectedin
    Biosimilar and specialty codesmixed
    Q5117trastuzumab-anns (biosimilar) Q-code
    Q5114trastuzumab-dkst (biosimilar)
    Q5135tocilizumab-aazg (biosimilar)
    Q9999ustekinumab-aauz (biosimilar)
    Q5098ustekinumab-srlf (biosimilar)
    J1412gene therapy code (valoctocogene roxaparvovec-rvox)
    HCPCS/J-codes shownHCPCS
    J3380listed for vedolizumab
    J3385listed for velaglucerase alfa / velmanase alfa
    J0217listed for velmanase alfa
    J8999multiple oral/oncolytic/other drugs
    J8499multiple drugs (e.g., vigabatrin, vibegron, vortioxetine)
    J3396listed for verteporfin
    J3397listed for vestronidase alfa-vjbk
    J9360listed for vinblastine sulfate
    J9370listed for vincristine sulfate
    J9390listed for vinorelbine tartrate
    1–10 of 20
    1/2
    Policy effective date and key PA metadata
    Policy effective dateEffective 08/01/2026
    Prior authorization requirementAll drugs on this list require prior authorization; submit to the reviewer listed for each drug (ESI, CCUM, eviCore) or to WPS if delegated reviewers cannot complete the review.
    Reviewer routing & contactsReviewer field indicates ESI (option 1), CCUM (option 2), eviCore (option 3); WPS contact and reviewer phone numbers are provided for submission routing (e.g., 1-800-475-1954 WPS; 1-800-333-5003 eviCore).
    Benefit type codesP = Pharmacy; M = Medical (benefit type is shown in Description, field 2).
    Required PA submission elementsInclude Alt Description/brand, Benefit Type (P/M), HCPCS/J/Q code when available, and route to the designated reviewer as shown in the drug entry.
    Numeric thresholds and coding/administrative notes
    Numeric clinical thresholdsN/A — No numeric clinical thresholds or per-patient numeric limits are specified in this document window.
    Coding examples included (selected)Document includes miscellaneous HCPCS/J-codes and Q-codes used across entries (examples listed inline such as J3490, J3590, J0889, J9145, J0881, J0882, J9011, J9000, Q2050, L8605, J1932, J0593).
    PA consequenceFailure to obtain prior authorization for any drug on the list may result in denial or the claim not being processed under the PA workflow.
    If PBM differsIf using a PBM other than ESI through WPS, submit to that PBM as indicated (including pharmacy drugs reviewed by ESI or eviCore).

    Provider Actions and Submission Requirements

    Prior Authorization

    Prior authorization required for all listed drugs

    All drugs shown on the PA roster require prior authorization; if delegated reviewers (ESI, CCUM, or eviCore) cannot complete the review, submit the request to WPS (or to the PBM used by the group when different from ESI).

    • PLEASE NOTE: All drugs on this list require a PA.
    • If ESI, CCUM, or eviCore cannot complete the review, submit to WPS for evaluation.
    • If using a PBM other than ESI through WPS, submit to that PBM.
    Prior Authorization

    Submit PA to the designated reviewer listed per drug

    Prior authorization must be submitted to the reviewer designated in the drug entry (ESI, CCUM, eviCore, or WPS). Use the reviewer assigned for each line item when routing PA requests.

    • Description field 4 = Reviewer (ESI, CCUM, eviCore or WPS) and must be used for submission.
    • Reviewer options: ESI (option 1), CCUM (option 2), eviCore (option 3); WPS is the fallback when external reviewers cannot complete review.
    Prior Authorization

    Obtain PA for every drug on the list (per-drug routing)

    A prior authorization is required for any drug that appears on this list; each drug entry specifies benefit type and billing code(s) and identifies the reviewer to receive the PA.

    • Each line includes: Alt Descriptions; Benefit Type (P = Pharmacy, M = Medical); HCPCS/J-code(s); Reviewer; Drug comments.
    • Route the PA to the reviewer shown for that drug.
    Prior Authorization

    PA required — use the reviewer indicated per drug

    All drugs on the roster require prior authorization; the document lists the specific reviewer (ESI, CCUM, eviCore, or WPS) for each drug and that reviewer must be used unless they cannot complete the review.

    • If external reviewer cannot complete review, submit to WPS.
    • Benefit type and HCPCS code are shown per-drug and should be included with the PA.
    Prior Authorization

    PA required — reviewers identified per drug (contact info provided)

    All drugs require prior authorization; reviewer assignments and contact routing (ESI, CCUM, or eviCore) are provided for each entry and must be followed when submitting PA requests.

    • Description fields define where to find reviewer and benefit type (Description 2 = Benefit Type; Description 4 = Reviewer).
    • Primary contact routing shown; phone numbers for reviewers and WPS are provided in the document.
    Documentation Required

    Include benefit type and HCPCS/J-code and send PA to assigned reviewer

    Prior authorization is required for every drug listed; include the drug identifier, benefit type, and HCPCS/J-code(s) as shown on the line item and route the request to the assigned reviewer.

    • Provide Alt Descriptions (brand/name), Benefit Type (P or M), HCPCS code, and any Drug Comments when submitting the PA.
    • PA submissions should be sent to ESI (option 1), CCUM (option 2), eviCore (option 3), or WPS when external reviewers cannot complete the review.
    Prior Authorization

    Route PA to the reviewer shown; submit to WPS if reviewer unavailable

    All drugs listed require prior authorization and must be routed to the designated reviewer (ESI, CCUM, eviCore); if those reviewers cannot complete the review, submit to WPS or the PBM used by the group.

    • When external reviewers cannot complete a review, WPS is the fallback for evaluation.
    • If the group uses a different PBM than ESI through WPS, submit to that PBM for review.
    Documentation Required

    Provide medical records and supporting clinical evidence with PA

    Documented sources used in review include the patient’s medical records, FDA-approved labeling, published peer‑reviewed literature, and evidence‑based guidelines; provide these materials as needed when submitting a PA.

    • Medical records describing the patient’s condition and prior treatments.
    • FDA‑approved labeling and published peer‑reviewed scientific literature or evidence‑based guidelines.
    Documentation Required

    Required submission details: drug ID, benefit type, and HCPCS/J-code

    PA submissions must identify the drug (alt description/brand), indicate benefit type (P = Pharmacy or M = Medical), include the applicable HCPCS/J-code(s), and note any drug comments (e.g., Oncology, MH/SUD).

    • Description 1 = Alt Descriptions; 2 = Benefit Type; 3 = HCPCS Code; 4 = Reviewer; 5 = Drug Comments.
    • Include the HCPCS or other billing code shown on the drug line when submitting the PA.
    Denial Risk

    No PA submitted = risk of denial or non‑processing

    If a PA is not obtained for any drug on this list, the claim or drug request may be denied; the document repeatedly warns that failure to submit required prior authorization risks denial.

    • PLEASE NOTE: All drugs on this list require a PA.
    • Failure to submit PA may result in the drug not being processed under the PA workflow or in denial of coverage.
    Prior Authorization

    Submit to the correct designated reviewer (avoid misrouting)

    Submit the PA to the reviewer listed in the drug entry (ESI, CCUM, or eviCore); when external reviewers cannot complete the review submit to WPS. Submitting to the wrong reviewer can delay or affect approval.

    • Reviewer field (Description 4) indicates the correct reviewer to receive the PA.
    • If external reviewer cannot complete the review, submit to WPS for evaluation.
    Note

    Where to obtain step‑therapy and PA criteria from delegated reviewers

    Where step therapy or clinical criteria are managed by delegated vendors, obtain criteria from the vendor: call 1-800-475-1954 for ESI/CCUM or view eviCore clinical guidelines online; confirm gene therapy coverage with WPS Customer Service.

    • For ESI or CCUM questions call 1-800-475-1954.
    • For eviCore guidelines see https://www.evicore.com/provider/clinical-guidelines and search for 'WPS Health Insurance'.
    • Confirm Gene Therapy coverage with WPS Customer Service using the number on the member’s card.
    Step Therapy

    Step therapy not specified in this document — check reviewer guidelines

    The document does not specify step‑therapy sequences or required prior failures in the excerpt; providers must rely on the designated reviewer’s clinical guidelines for any step‑therapy requirements.

    • No explicit step‑therapy algorithms are provided in these chunks; routing and reviewer assignment are shown instead.
    • Delegated reviewers (ESI, CCUM, eviCore) maintain step therapy/criteria and will apply them during review.
    Billing Rule

    Include HCPCS/J/Q code and route PA to the reviewer listed

    When submitting a PA, include the drug identifier and the applicable HCPCS/J/Q code(s) as listed on the drug line and route the submission to the reviewer shown (ESI, CCUM, eviCore or WPS).

    • Include Alt Descriptions, Benefit Type, HCPCS code, Reviewer, and Drug Comments as provided on the line item.
    • Contact numbers for reviewers and WPS are provided in the document for submission routing.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Definitions and Field Mapping

    Prior authorization — A review process to confirm appropriate use and medical necessity of certain drugs prior to coverage.
    DefinitionA review process to confirm appropriate use and medical necessity of certain drugs prior to coverage.
    PurposeEnsure drugs meet medical necessity and appropriate use before coverage is authorized.
    Decision inputsMedical records, FDA labeling, peer-reviewed literature, and evidence-based guidelines are used in decision-making.
    Benefit Type codes — P = Pharmacy benefit; M = Medical benefit.
    PPharmacy benefit
    MMedical benefit
    UsageBenefit Type codes (P/M) are shown in the Description, 2 field for each drug entry.
    Drug Comments tag — MH/SUD indicates mental health/substance use disorder; some entries include clinical context like 'Oncology'.
    Drug Comments tag (example)MH/SUD indicates mental health/substance use disorder; entries may also include context such as 'Oncology'.
    Field locationDrug Comments appear as Description, 5 in the per-drug list entries.
    Clinical flagsUsed to flag special program contexts (e.g., Oncology, Gene Therapy, Radiation Oncology).
    Description fields — Field definitions in the list: 1 = Alt Descriptions; 2 = Benefit Type (P = Pharmacy, M = Medical); 3 = HCPCS Code; 4 = Reviewer (ESI, CCUM, eviCore...
    Field mapping summaryDescription fields define per-line data: 1 = Alt Descriptions; 2 = Benefit Type; 3 = HCPCS Code; 4 = Reviewer; 5 = Drug Comments.
    Example of useEntries show Alt Descriptions, Benefit Type (P/M), HCPCS codes, Reviewer assignment (ESI/CCUM/eviCore/WPS), and Drug Comments.
    Reviewer contactReviewer field includes routing and contact information (WPS: 1-800-475-1954; eviCore: 1-800-333-5003).
    Benefit Type — P = Pharmacy, M = Medical (as shown in the document columns).
    Benefit Type mappingP = Pharmacy; M = Medical
    Displayed locationShown in Description, 2 field for each drug entry in the list header and per-line entries.
    ImplicationBenefit Type determines claim routing (pharmacy vs medical) and reviewer assignment.
    Drug Comments — Annotations such as MH/SUD = mental health/substance use disorder and Oncology indicating special clinical program context.
    Drug Comments examplesMH/SUD = mental health/substance use disorder; Oncology and Gene Therapy also appear as comments.
    Field numberDrug Comments are captured in Description, 5 for each drug line.
    Use caseComments flag clinical program context to guide reviewer routing (e.g., oncology items routed to eviCore).
    Benefit Type — Benefit Type P = Pharmacy; M = Medical
    Benefit Type codes (concise)P = Pharmacy; M = Medical
    Where shownAppears in Description, 2 for each per-drug entry and in section headers indicating Benefit Type mapping.
    Claims implicationDetermines whether drug is processed under pharmacy or medical benefit and reviewer routing.
    P = Pharmacy; M = Medical — Benefit Type
    Benefit Type (single-letter)P = Pharmacy; M = Medical
    Displayed fieldShown in Description field 2 for each drug line in the list.
    Routing impactUsed to guide whether ESI/CCUM/eviCore or other reviewer should handle the PA.
    Reviewer — Reviewer options indicate which entity will review PA requests: ESI (option 1), CCUM (option 2), eviCore (option 3), or WPS.
    Reviewer optionsESI (option 1), CCUM (option 2), eviCore (option 3), or WPS (fallback)
    Fallback ruleIf delegated reviewers cannot complete the review, submit the PA to WPS for evaluation.
    Contacts referencedWPS and reviewer phone numbers are provided in the document (e.g., WPS: 1-800-475-1954; eviCore: 1-800-333-5003).
    P = Pharmacy; M = Medical — Benefit Type
    Benefit Type mappingP = Pharmacy; M = Medical
    Where usedExplicitly listed in the per-drug Description, 2 field across the document.
    Effect on processingDetermines claim type and appropriate reviewer routing listed per drug.
    MH/SUD indicates mental health/substance use disorder comments — Drug Comments
    Drug Comments meaningMH/SUD indicates mental health/substance use disorder comments in per-drug entries.
    Field positionAppears as Description, 5 for each drug entry.
    Example contextsAlso used to flag Oncology, Gene Therapy, CAR-T, Radiation Oncology where applicable.
    Benefit Type codes — Benefit Type P = Pharmacy; M = Medical (as used in the Description, 2 field).
    Benefit Type codesP = Pharmacy; M = Medical
    Document usageUsed in Description field 2 across the list to indicate benefit coding for each drug.
    Reviewer linkageBenefit Type pairs with Reviewer field to determine routing (ESI/CCUM/eviCore).
    Description field mapping — Description fields: 1 = Alt Descriptions; 2 = Benefit Type; 3 = HCPCS Code; 4 = Reviewer (ESI, CCUM, eviCore, or WPS); 5 = Drug Comments ...
    Description field mapping1 = Alt Descriptions; 2 = Benefit Type; 3 = HCPCS Code; 4 = Reviewer (ESI, CCUM, eviCore, or WPS); 5 = Drug Comments.
    Per-line structureEach drug line follows this mapping so PA submissions can include the corresponding fields.
    Reviewer contact noteReviewer field includes routing and phone contacts for WPS and reviewers as needed.
    Benefit type and comment codes — P = Pharmacy benefit; M = Medical benefit; MH/SUD = mental health/substance use disorder
    Benefit type codes and commentsP = Pharmacy; M = Medical; MH/SUD = mental health/substance use disorder
    Where shownDisplayed in Description fields across the list header and per-drug rows.
    PurposeUsed to annotate clinical program context and guide reviewer selection.
    Benefit type — Benefit Type P = Pharmacy
    Benefit Type (P)P = Pharmacy
    Displayed locationShown in Description, 2 for pharmacy-designated entries.
    ImplicationIndicates pharmacy benefit processing and reviewer routing (often ESI).
    Description field mapping — Description fields: 1 = Alt Descriptions; 3 = HCPCS Code; 4 = Reviewer; 5 = Drug Comments (e.g., MH/SUD)
    Field mapping (alternate) Description fields include: 1 = Alt Descriptions; 3 = HCPCS Code; 4 = Reviewer; 5 = Drug Comments (e.g., MH/SUD).
    NoteThe document repeats mapping variations in different sections but consistently uses these data elements per line.
    Use in submissionsSubmitters should include the listed HCPCS/benefit type and reviewer when requesting PA.
    P — Benefit Type P = Pharmacy
    P = PharmacyBenefit Type P = Pharmacy
    ContextUsed in Description, 2 across the document's drug list headers and rows.
    Reviewer linkPharmacy-designated items often route to ESI (option 1) or the PBM listed.
    Reviewer routing — Reviewer options listed as ESI, CCUM, eviCore, or WPS with contact numbers for WPS and reviewer phone routing
    Reviewer routing optionsESI (option 1), CCUM (option 2), eviCore (option 3), or WPS as fallback
    Contact detailsDocument includes phone routing and contacts for reviewers and WPS (e.g., WPS: 1-800-475-1954; eviCore: 1-800-333-5003).
    Routing ruleIf delegated reviewers cannot complete review, submit to WPS or the PBM indicated for that group.
    Benefit Type codes — P = Pharmacy; M = Medical (explicitly listed in document descriptions).
    Benefit Type codesP = Pharmacy; M = Medical
    Document usageShown in per-drug Description field 2 across the list to indicate benefit coding.
    Routing impactBenefit Type helps determine reviewer assignment and claim type.
    Reviewer options — Reviewer field indicates which entity performs PA review: ESI (option 1), CCUM (option 2), eviCore (option 3), or WPS; phone contacts for...
    Reviewer field purposeIndicates which entity performs PA review: ESI (option 1), CCUM (option 2), eviCore (option 3), or WPS (fallback)
    Submission instructionSubmit PA to the reviewer listed for the drug; if they cannot complete review, submit to WPS.
    Benefit Type Codes — P = Pharmacy, M = Medical (as used in the list).
    Benefit Type codes (short)P = Pharmacy; M = Medical
    Per-line usageAppears in Description field 2 for each listed drug to denote benefit.
    EffectUsed to determine billing pathway and reviewer selection.
    HCPCS/J-codes — Billing codes used for many drugs in the list (examples included inline such as J3380, J8999, J8499).
    HCPCS / J-codes usageMany drugs in the list include HCPCS/J-codes (examples: J3380, J8999, J8499, J3392, J9331)
    Where listedHCPCS/J-codes appear in Description, 3 for each drug entry in the per-drug list.
    Billing implicationInclude the HCPCS/J/Q code when submitting PA to the designated reviewer.

    Initial Prior Authorization Metadata

    Initial PA metadata (no clinical criteria in excerpt)

    Per‑drug PA routing and metadata (no clinical criteria in excerpt)

    Initial PA metadata: Each drug entry provides: (1) display/brand name(s); (2) Benefit Type (P = Pharmacy or M = Medical); (3) HCPCS/J‑code(s) where applicable; (4) designated reviewer (ESI, CCUM, eviCore, or WPS); and (5) Drug comments (e.g., Oncology, MH/SUD).

    This section contains administrative metadata used to submit PA requests; clinical necessity criteria are maintained by the designated reviewers and are not present in the provided excerpt.

    Step Therapy and Vendor Criteria

    Step therapy summaryWhere to obtain details / reviewerNotes
    Step therapy and prior authorization criteria are maintained by delegated reviewers; this document does not list internal step sequences
    ESI/CCUM: call 1-800-475-1954; eviCore: https://www.evicore.com/provider/clinical-guidelines (search 'WPS Health Insurance')
    Providers should contact the designated reviewer for specific step therapy or clinical-criteria requirements; confirm gene therapy coverage with WPS Customer Service
    Step therapy present?Evidence in documentAction for providers
    No — document is a prior authorization (PA) drug list and does not define step edits
    Multiple entries state 'PLEASE NOTE: All drugs on this list require a PA' and list reviewer routing and benefit type but no step rules
    Submit PA to the reviewer listed for the drug (ESI, CCUM, eviCore) or to WPS if reviewers cannot complete review
    Step-therapy sequences specified?Reviewer routing shown?Implication
    No — no step-therapy sequences are specified in these chunks
    Yes — drugs include a 'Reviewer' field indicating ESI (option 1), CCUM (option 2), or eviCore (option 3) as appropriate
    Clinical determinations, including any step-therapy checks, are handled by the assigned reviewer—providers must follow reviewer criteria
    Document specifies step therapy sequences?Reviewer assignment examplesRecommended provider step
    No — document routes drugs to external reviewers for clinical determination rather than listing step sequences
    Examples: cabazitaxel → eviCore (option 3); cabotegravir → CCUM (option 2); many oncology agents routed to eviCore
    Submit PA with required clinical documentation to the reviewer listed; follow that reviewer’s clinical guideline for step requirements
    Benefit type / step therapy detailDoes it list prior failures or steps?Reviewer implications
    Entries include Benefit Type flags (P = Pharmacy, M = Medical) and reviewer routing metadata
    No — these chunks do not specify required prior failures or explicit step therapy steps
    Benefit-type and reviewer mapping guide where to submit PA; clinical criteria (including steps) are determined by the reviewer
    Routing options notedReviewer option codesStep-therapy sequencing documented?
    Routing options to different reviewers are provided; document annotates reviewer option numbers per drug
    ESI = option 1; CCUM = option 2; eviCore = option 3; WPS is fallback if reviewer cannot complete review
    No — the document includes routing options but does not specify step-therapy sequencing or required prior failures
    Route to designated reviewerPA requirementDocument guidance
    Route PA to the reviewer listed for each drug: ESI, CCUM, eviCore, or WPS as indicated
    All listed drugs require prior authorization before coverage as stated repeatedly in the document
    If delegated reviewers cannot complete review, submit to WPS; if group uses a different PBM, submit to that PBM per instructions
    Step therapy sequences listed?PA requirement shown?Provider take-away
    No — these excerpts do not list step therapy sequences or required prior drug failures
    Yes — the entries show 'All drugs on this list require a PA' and include reviewer routing and benefit type per drug
    Providers must submit PA to the reviewer indicated and follow that reviewer’s clinical guidelines for any step-therapy rules
    Provider submission requirementWhere to send PAStep therapy detail availability
    Providers must submit prior authorization requests for listed drugs and include required identifiers (benefit type, HCPCS/J-code where applicable)
    Submit to the assigned reviewer (ESI, CCUM, eviCore) as specified per drug; if reviewer cannot complete the review, submit to WPS; if another PBM is used, submit to that PBM
    Specific step therapy criteria are not included in this list; obtain step therapy/clinical criteria from the delegated reviewer (call 1-800-475-1954 for ESI/CCUM or view eviCore clinical guidelines online)

    Site of Care and Benefit Type Implications

    Billing Rule

    Use provided reviewer contacts for PA submission

    Use the reviewer contact and routing information provided in the document: main WPS routing and reviewer phone numbers (e.g., 1‑800‑475‑1954 for ESI/CCUM routing and reviewer contacts) are shown for PA submission questions.

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Biosimilars Listed

    Note
    Note
    Note
    Note
    Note
    Note

    Background

    Prior authorization is used to ensure appropriate use of certain drugs and to confirm that a requested drug meets the plan's medical necessity requirements. Reviewers rely on medical records, FDA‑approved labeling, peer‑reviewed literature, and evidence‑based guidelines when determining coverage. Services deemed experimental, investigational, or unproven under the clinical guidelines are not covered.